Skip to main content

Table 4 Treatment Loss to follow up and treatment outcomes for TB patients, and Treatment Loss to follow up, Glucose monitoring and Retentions into Care by people living with DM

From: Bidirectional screening and treatment outcomes of diabetes mellitus (DM) and Tuberculosis (TB) patients in hospitals with measures to integrate care of DM and TB and those without integration measures in Malawi

Treatment outcomes and DM Patients retention:

 

A. Tuberculosis Patients

 

Variables

Totals

n = 602 (100%)

Integrated

n = 94 (15.6%)

Non-Integrated

n = 508 (84.4%)

RD (%) (95%CI)

RD (%) (95%CI) as controlled by both Sex and Age

Treatment Outcomes

     

Treatment Loss to follow up

71 (11.8%)

0

71 (14.0%)

-14.0 (-17.0,-11.0)

-

Treatment Success

486 (80.7%)

87 (92.5%)

399 (78.5%)

14.0 (7.6,20.4)

14.3 (10.7,17.8)

Died

45 (7.5%)

7 (7.4%)

38 (7.5%)

-0.1 (-3.2,3.1)

-0.4 (-3.5,2.8)

B. People with Diabetes mellitus

 
 

Total: N = 557 (100%)

Integrated care: n = 64 (11.5%)

Non-Integrated care: n = 493 (88.5%)

RD (%) (95%CI)

RD (%) (95%CI) as controlled by both Sex and Age

Treatment outcomes Outcome

 

On treatment & transferred out

508 (91.2%)

61 (95.3%)

447 (90.7%)

4.6 (-1.1,10.4)

5.0 (-1.1,11.1)

Loss to follow up & stopped

42 (7.5%)

2 (3.1%)

40 (8.1%)

-5.0 (-10.0,-0.0)

-5.3 (-10.4,0.0)

Died

7 (1.3%)

1 (1.6%)

6 (1.2%)

0.4 (-2.8, 3.5)

0.3 (-3.1, 3.7)

Quarterly FBG Checks (n, %)

FBS checked at 6 months

153 (27.5%)

27 (42.2%)

126 (25.6%)

16.6 (4.7,28.5)

16.4 (4.5,28.4)

FBS checked at 12 months

138 (24.8%)

32 (50.0%)

106 (21.5%)

28.5 (15.3,41.7)

28.1 (15.4,40.9)

Years in Care Since Enrolment (n, %)

 ≤ 1 Year

311 (55.8%)

24 (37.5%)

287 (58.2%)

-20.7 (-33.4,-8,1)

2 to 3 Years

128 (23.0%)

28 (43.8%)

100 (20.3%)

23.5 (10.8,36.1)

4 to 5 Years

52 (9.3%)

5 (7.8%)

47 (9.5%)

-1.7 (-8.8,5.4)

6 to 7 Years

40 (7.2%)

3 (4.7%)

37 (7.5%)

-2.8 (-8.5,2.9)

 ≥ 8 Years

26 (4.7)

4 (6.3%)

22 (4.5%)

1.8 (-4.4,8.0)

  1. Showing treatment outcomes for TB patients and treatment loss to follow, glucose monitoring and retentions into care among people with DM